title: Screening for EGFR mutations in lung cancer.
abstract: Certain mutations in the epidermal growth factor receptor (EGFR) gene confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small cell lung cancer. Large-scale screening for EGFR mutations in such patients is feasible for predicting response to TKIs and thus guiding treatment.
authors.affiliation: Medical Oncology Service, Pangaea Biotech, USP Institut Universitari Dexeus, Barcelona, Catalunya, Spain.
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Molina-Vila
authors.forename: Jordi
authors.initials: J
authors.lastname: Bertran-Alamillo
authors.forename: Clara
authors.initials: C
authors.lastname: Mayo
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
mesh_terms: D066246:ErbB Receptors / Q000097:blood / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000235:genetics*; D009154:Mutation / Q000235:genetics*; D016133:Polymerase Chain Reaction
chemical_list: D066246:ErbB Receptors